Based on a single-variable model, the GUIDE-IT trial demonstrated that NT-proBNP-guided therapy was not more effective than usual care for improving outcomes in high-risk patients with HF and reduced EF [70]. This evidence concerns the gene NPPB and hydrops fetalis.